Please login to the form below

Not currently logged in
Email:
Password:

Microbiome specialist Rebiotix chalks up C. diff trial success

Drug therapy can prevent recurrent infections

drugs

Rebiotix says its microbiota suspension RBX2660 has prevented recurrences of troublesome Clostridium difficile infections in a mid-stage trial and will be advanced into phase III.

The Minnesota-based company is a specialist in using suspensions of bacterial cultures to restore the natural balance of the bacterial colonies that populate our bodies - known as the microbiome - which can become disrupted by disease or drug therapies.

In the PUNCH open-label trial, RBX2660 given as two separate doses a week apart met its primary objective of reducing the recurrence of C. diff infections, which often occur as a consequence of antibiotic therapy for other infections when added to standard antibiotic therapy.

Almost 79% of patients on Rebiotix's therapy had no recurrence over the course of the study, which compares favourably with a historical control rate of 52% says the company.

While unpleasant, C. diff infections are generally not life threatening and can usually be treated effectively with another course of antibiotics. In some cases however, damage to the bowel or severe dehydration can result and the infection can be much more serious in patients with compromised immune systems.

Rebiotix's chief executive Lee Jones said the results suggest that a "broad-spectrum microbiota drug product [can] rehabilitate the gut microbiome and break the cycle of C. diff recurrence".

The microbiome is fast becoming a hot topic in the pharma industry, with several companies exploring whether therapies based on bacterial suspensions - or drugs from microbiome-derived targets - can tackle a range of not only gastrointestinal diseases but also cancer, diabetes, and central nervous system disorders like Parkinson's and multiple sclerosis.

Takeda has been actively seeking out companies working in this area - forging deals with Enterome (which is also working with Bristol-Myers Squibb), Finch Therapeutics and most recently NuBiyota to build a portfolio of microbiome technologies. Johnson & Johnson's Janssen unit has set up a research institute dedicated to microbiome studies, and food giant Nestle is also getting involved with a $1.9bn partnership with microbiome specialist Seres that is spearheading a push into pharma.

Meanwhile, other emerging strategies for the prevention of C. diff recurrence include antibodies like Merck & Co's recently-approved Zinplava (bezlotoxumab) - which works by neutralising toxins secreted by the bacterium - and prophylactic vaccines, such as Pfizer's PF-06425090 and Sanofi Pasteur's ACAM-CDIFF which are both in late-stage testing.

Article by
Phil Taylor

13th April 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Quintiles

With a network of more than 27,000 employees conducting business in approximately 100 countries, we have helped develop or commercialize...

Latest intelligence

Anthill_icon_Green_02_Digital.png
How to get your sales force to use digital tools
You have the perfect digital strategy. You provide the most advanced digital sales tools. You power it with amazing content. And then discover that customer-facing staff aren’t using it. Wait....
Highlights: Ashfield leads by example, engaging attendees at Pharma Forum
During this year’s Pharma Forum, held at the Gaylord National Convention Center in National Harbor, Maryland, David Kerr (Senior Director of Creative & Production Services) co-hosted an insightful session surrounding...
How to find pharma content that inspires your audience
Getting your customers’ attention begins with presenting pharma content that speaks to their needs and wants effectively....

Infographics